Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : 1000% returns are cool !!! -- Ignore unavailable to you. Want to Upgrade?

To: If only I'd held who wrote (656)	6/8/2000 9:13:00 AM
From: vagabond	Read Replies (1) \| Respond to of 3326

DNA being sued by CHIR... ==================== Thursday June 8, 5:00 am Eastern Time SOURCE: Chiron Corporation Chiron Files Patent Infringement Action Against Genentech Genentech's Herceptin Infringes Chiron Monoclonal Antibody Patents, Chiron Alleges EMERYVILLE, Calif., June 8 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR - news) today filed a patent infringement lawsuit against Genentech alleging that the manufacture and sale of Herceptin© (trastuzumab), an anti-HER-2 monoclonal antibody, infringes Chiron's U.S. Patent No. 6,054,561 (the '561 patent). The suit was filed in the United States District Court for the Eastern District of California. Chiron was granted the '561 patent on April 25, 2000. This patent is directed to monoclonal antibodies that bind selectively to human breast cancer cells, specifically, the c-erbB-2 (HER-2) antigen. The newly issued patent is the latest in a series of patents first issued in 1988 to Cetus Corporation, which later was acquired by Chiron. These patents, based upon an application originally filed in 1984, reflect Chiron's work to identify specific antigens that can be used to diagnose and treat breast cancer. Chiron scientists, including '561 patent inventors David Ring, Ph.D and Arthur Frankel, Ph.D., are acknowledged to have pioneered development of the first anti-c-erbB-2 monoclonal antibody, which laid the foundation for many future approaches to cancer diagnostics and immunotherapy. ``We wholly support the application of this monoclonal antibody technology to benefit the breast cancer community and are excited to license the technology, on commercially reasonable terms, to Genentech and others,'' commented Robert Blackburn, Chiron's vice president and chief patent counsel. ``So far, our negotiations with Genentech have failed to result in a viable license agreement for Herceptin, and thus we are compelled to bring legal action to protect our patent property. Chiron has not sought injunctive relief and Herceptin is anticipated to remain on the market while a patent resolution is sought.'' Chiron currently markets Proleukin© (aldesleukin) for treatment of metastatic renal cell cancer and metastatic melanoma, DepoCyt(TM) (cytarabine liposome injection) for the treatment of lymphomatous meningitis, and Cardioxane© (dexrazoxane) for the treatment of chemotherapy induced cardiotoxicity. Chiron has made a significant investment in advancing a novel portfolio of small molecule, protein and antibody-based cancer research programs. Monoclonal antibody research is an important component of Chiron's ongoing effort to understand the biology of cancer and to identify effective disease treatments. About Chiron Corporation Chiron Corporation, headquartered in Emeryville, California, is a leading biotechnology company that participates in three global healthcare markets: biopharmaceuticals, vaccines, and blood testing. The company is applying a broad and integrated scientific approach to the development of innovative products for preventing and treating cancer, infection and cardiovascular disease. For further information, visit the company's website at www.chiron.com. This document contains forward-looking statements that are subject to risk and uncertainty. There are a number of factors that could cause the company's actual performance to differ materially from expectations. These and other factors investors should consider are more thoroughly described in the company's Securities and Exchange Commission filings, including the Form 10-Q and Form 10-K.

To: If only I'd held who wrote (656)	6/8/2000 9:17:00 AM
From: vagabond	Read Replies (1) \| Respond to of 3326

FMKT news... ============== Thursday June 8, 8:00 am Eastern Time SOURCE: FreeMarkets, Inc. FreeMarkets and Xelus Form Strategic Alliance to Deliver Web-Based B2B eMarketplace and Decision Support Solutions Companies Offer Comprehensive eBusiness Solutions to Global 1000 Organizations In Service Industries PITTSBURGH, and ROCHESTER, N.Y., June 8 /PRNewswire/ -- FreeMarkets, Inc. (Nasdaq: FMKT - news), the original and world's leading B2B eMarketplace, and Xelus, Inc. (formerly LPA, Inc.), the leading provider of inventory planning, forecasting, optimization and e-commerce solutions for service industries, announced today that they have formed a strategic alliance to deliver web-based B2B e-trading communities and decision support solutions to Global 1000 organizations. Under the terms of the alliance, FreeMarkets and Xelus will provide Global 1000 organizations in industries including aerospace, telecommunications, high technology and utilities with access to the FreeMarkets© B2B eMarketplace and Xelus's money-saving supply chain optimization and planning for service inventory. The FreeMarkets B2B eMarketplace has driven over $5.4 billion in commerce to date and includes industry-leading online auction technology, technical operations, industrial market making services, access to a global database of suppliers and supplier research, and call center support to buyers and suppliers in over 30 languages. Xelus's offerings combine sophisticated planning and forecasting capabilities with e-Business functionality to create multi-tiered e-trading communities that facilitate collaborative commerce in selected verticals. Through the alliance, customers can enhance the efficiency of the procurement process and increase potential savings by combining the FreeMarkets and Xelus solutions. Customers using the FreeMarkets B2B eMarketplace, for example, will be able to use the FreeMarkets Desktop, the industry's only web-based technology sourcing platform for industrial buyers, to prepare for bidding events and integrate Xelus's decision support solutions for materials purchasing and re-order. ``Xelus has a leading optimization solution for the service industry, with applications controlling over $50 billion worth of yearly service parts purchases at Fortune 500 companies worldwide and FreeMarkets' customers have conducted over $5.4 billion worth of purchases through our B2B eMarketplace,'' said Scott Grimes, vice president of business development for FreeMarkets. ``Together, we can provide additional value to Global 1000 organizations by offering a combined solution that increases sourcing efficiency and saves money.'' ``Our partnership with FreeMarkets will enable Xelus to implement online sourcing solutions that will have immediate and long-term impact on our clients,'' said Rudy George, vice president of alliances. ``Our distinctive expertise in aviation, telecommunications, high-tech and utilities complement the FreeMarkets B2B eMarketplace, providing one-of-a-kind optimized supply chain solutions for the service industry.'' About Xelus Xelus, Inc., a privately held company headquartered in Rochester, NY, is the market leader in providing inventory planning, forecasting, optimization and e-commerce solutions for service, maintenance, repair and overhaul operations to Global 1000 organizations in the aviation, telecommunications, high-tech, rail, and utilities industries. Xelus' software solutions combine sophisticated planning and forecasting capabilities with e-Business functionality to create multi-tiered e-trading communities that facilitate collaborative commerce in selected verticals. Xelus offers unsurpassed service optimization that helps enterprises achieve dramatic new levels of efficiency, improved ROI, increased customer satisfaction, enlarged market share, and enhanced global market opportunities. Xelus maintains offices throughout the United States and Europe. For more information visit www.xelus.com. About FreeMarkets FreeMarkets is the original and world's leading B2B eMarketplace, with online markets for industrial parts, raw materials, commodities and services. The Company has executed online auctions for over $5.4 billion of purchase orders to date, and created potential estimated savings of more than $1 billion for its customers. Since 1995, FreeMarkets has created online auctions for products in more than 100 supply verticals, including injection molded plastic parts, commercial machinings, metal fabrications, chemicals, printed circuit boards, corrugated packaging and coal. More than 4,000 suppliers from over 50 countries have participated in the FreeMarkets B2B eMarketplace. FreeMarkets is the only B2B eMarketplace that includes industry-leading online auction technology, technical operations, industrial market making services, access to a global database of suppliers and supplier research, call center support to buyers and suppliers in over 30 languages, and marketplace rules. The Company's current customers include Visteon Corporation, United Technologies Corporation, The Quaker Oats Company, Owens Corning, Eaton Corporation, Emerson Electric Company, FirstEnergy Corp., SmithKline Beecham plc, Navistar International and Delphi Automotive Systems Corporation. FreeMarkets can be found on the Web at www.freemarkets.com. FreeMarkets is a registered trademark of FreeMarkets, Inc.